Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells | Synapse

January 1, 2012Open Access

CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Despite intensive study, the role of CCR5 in cancer remains elusive. We showed that CCR5 expression by both CD4+ and CD8+ T cells is necessary to boost anti-tumor responses by optimizing helper-dependent CD8+ T cell priming. Our findings could have implications for cancer treatment in patients with defective CCR5 expression.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

González-Martín et al. (Sun,) studied this question.

synapsesocial.com/papers/6a1c488700ee29383e9dba46 https://doi.org/https://doi.org/10.4161/onci.1.1.17995

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1CCL5 as an adjuvant for cancer immunotherapy2010 · 89 citations
2CD4+ T Cells Elicit Host Immune Responses to MHC Class II− Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells2010 · 79 citations
3Cancer Immunotherapy by Dendritic Cells2008 · 506 citations
4The CD8<sup>+</sup> T cell repertoire against Her‐2/neu antigens in neu transgenic mice is of low avidity with antitumor activity2004 · 71 citations
5Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands2010 · 104 citations